Ophthalmology – Radiation Retinopathy

Basics

Description

Radiation retinopathy is a delayed, progressive occlusive retinal microangiopathy caused by previous therapeutic radiation involving the eye, orbit, or adjacent head and neck structures.

It may follow:

• Plaque brachytherapy
• Proton-beam therapy
• External-beam radiotherapy
• Stereotactic radiotherapy
• Other radiation delivered sufficiently close to the retina

The disorder resembles diabetic retinopathy because radiation damages the retinal capillary circulation, producing:

• Microaneurysms
• Retinal hemorrhages
• Cotton-wool spots
• Capillary nonperfusion
• Radiation macular edema
• Retinal neovascularization
• Vitreous hemorrhage
• Neovascular glaucoma

The major cause of vision loss is usually:

Radiation maculopathy with macular edema and/or macular ischemia.

Clinical Importance

Radiation retinopathy may remain asymptomatic until:

• Macular edema develops
• Macular ischemia becomes significant
• Neovascular complications occur

Modern management is centered largely on:

Intravitreal anti-VEGF therapy

for radiation maculopathy and retinal neovascularization.

This is a major change from older treatment paradigms that relied primarily on focal/grid laser.

Terminology

Radiation Retinopathy

Refers broadly to radiation-induced retinal microvascular disease.

Radiation Maculopathy

Refers specifically to radiation-induced vascular injury involving the macula, often causing:

• Macular edema
• Ischemia
• Hemorrhage
• Exudation

Radiation maculopathy is the most common vision-threatening manifestation.

Epidemiology

Incidence depends on:

• Total radiation dose
• Dose per fraction
• Radiation modality
• Volume of retina exposed
• Macular dose
• Optic disc dose
• Follow-up duration
• Patient vascular risk factors

Because onset may be delayed by years, prevalence increases with longer follow-up.

Latency

Radiation retinopathy generally appears:

Months to years after treatment

A common interval is approximately:

1–3 years

but onset may be:

• Earlier after high-dose exposure
• Delayed for many years

Therefore a remote history of ocular or orbital radiotherapy remains clinically relevant.

Risk Factors

Important risk factors include:

• Higher retinal radiation dose
• Larger dose per fraction
• Greater macular exposure
• Greater optic disc exposure
• Larger irradiated retinal volume
• Diabetes mellitus
• Hypertension
• Concurrent chemotherapy
• Preexisting retinal vascular disease
• Previous vascular compromise

Diabetes

Diabetes substantially increases susceptibility because both:

• Diabetes
• Radiation

damage the retinal microcirculation.

Patients with diabetes may develop:

• Earlier disease
• More severe macular edema
• More extensive ischemia

after a comparable radiation exposure.

Radiation Dose

With conventional fractionated radiotherapy, retinal toxicity becomes increasingly likely as cumulative retinal dose rises, particularly beyond approximately:

45–50 Gy

Risk is also influenced heavily by:

• Fraction size
• Exact retinal volume irradiated

There is no single completely “safe” retinal dose.

Brachytherapy

Radiation retinopathy is an important delayed complication of plaque treatment for:

• Choroidal melanoma
• Other selected intraocular tumors

Risk increases when the tumor lies close to:

• Fovea
• Optic disc

because these structures receive higher radiation doses.

Pathophysiology

Radiation causes:

Direct DNA injury + free-radical formation + microvascular endothelial damage

The retinal capillary endothelium is particularly vulnerable.

Capillary Injury

Radiation damages:

• Endothelial cells
• Pericytes
• Capillary basement membrane

leading to:

• Capillary incompetence
• Microaneurysm formation
• Vascular leakage
• Capillary closure

Retinal Ischemia

Progressive capillary occlusion produces:

Retinal nonperfusion

which drives expression of:

• VEGF
• Other angiogenic mediators

This may eventually cause:

• Retinal neovascularization
• NVD
• NVE
• NVI
• Neovascular glaucoma

Blood-Retinal Barrier Breakdown

Endothelial dysfunction produces:

• Leakage
• Intraretinal fluid
• Lipid exudation
• Cystoid macular edema

This is the basis of:

Radiation macular edema

and explains the effectiveness of VEGF inhibition.

Clinical Presentation

Patients may initially be:

Asymptomatic

Symptoms depend on the retinal region involved.

Possible complaints include:

• Blurred central vision
• Metamorphopsia
• Central scotoma
• Reduced contrast sensitivity
• New floaters
• Sudden visual loss from vitreous hemorrhage

Visual Loss

Vision may decline from:

• Macular edema
• Macular ischemia
• Foveal atrophy
• Vitreous hemorrhage
• Tractional retinal detachment
• Neovascular glaucoma
• Concurrent radiation optic neuropathy

Fundus Findings

Early findings may include:

• Microaneurysms
• Telangiectatic capillaries
• Dot-blot hemorrhages
• Cotton-wool spots
• Hard exudates

Later findings include:

• Capillary nonperfusion
• Macular edema
• Vascular sheathing
• Retinal neovascularization
• Optic disc neovascularization
• Vitreous hemorrhage

Microaneurysms

Microaneurysms are often among the earliest visible abnormalities.

They may appear:

• Around the macula
• Near irradiated tumor margins
• Within regions of vascular injury

Cotton-Wool Spots

Cotton-wool spots represent:

Focal retinal nerve fiber layer ischemia

and indicate significant microvascular compromise.

Retinal Hemorrhages

Hemorrhages may be:

• Dot-blot
• Flame-shaped
• Preretinal in proliferative disease

The overall pattern can closely mimic diabetic retinopathy.

Hard Exudates

Hard exudates result from chronic vascular leakage and may accumulate:

• Around microaneurysms
• Around the fovea

forming circinate patterns.

Radiation Macular Edema

Macular edema is a major cause of reduced central vision.

OCT may show:

• Intraretinal cysts
• Diffuse retinal thickening
• Subretinal fluid in selected cases
• Hyperreflective exudates

Macular Ischemia

Capillary closure involving the foveal circulation may produce:

• Enlarged or irregular FAZ
• Reduced capillary density
• Permanent central visual loss

Unlike edema:

Established macular ischemia has no proven restorative treatment.

Proliferative Radiation Retinopathy

Severe ischemia may result in:

• NVD
• NVE
• Preretinal hemorrhage
• Vitreous hemorrhage

This represents the proliferative stage.

Anterior Segment Neovascularization

Extensive retinal ischemia may cause:

• Neovascularization of the iris
• Neovascularization of the angle

leading to:

Neovascular glaucoma

Radiation Retinopathy vs Radiation Optic Neuropathy

Both may occur after ocular radiation.

Radiation Retinopathy

Primarily affects:

• Retinal microvasculature

Findings include:

• Microaneurysms
• Hemorrhages
• Exudates
• Macular edema
• Nonperfusion

Radiation Optic Neuropathy

Primarily affects:

• Optic nerve
• Chiasm

and produces:

• Dyschromatopsia
• RAPD
• Visual field loss
• Optic atrophy

Both disorders may coexist.

Diagnosis

Diagnosis is based on:

• Prior radiation exposure
• Compatible retinal examination
• Characteristic multimodal imaging
• Exclusion of competing vascular causes

History

Important questions include:

• Original tumor diagnosis
• Radiation modality
• Total dose
• Fractionation
• Date of treatment
• Plaque location if brachytherapy
• Tumor distance from fovea and disc
• Diabetes
• Hypertension
• Chemotherapy
• Previous retinal disease

Radiation oncology records are very useful when available.

Slit-Lamp Examination

Assess for:

• NVI
• Hyphema
• Cataract
• Radiation-related ocular surface disease

Intraocular Pressure

Measure IOP because severe ischemic disease may progress to:

Neovascular glaucoma

Gonioscopy

Perform gonioscopy when:

• NVI is present
• IOP is elevated
• Neovascular glaucoma is suspected

Look for:

• NVA
• PAS
• Angle closure

Dilated Fundus Examination

Evaluate:

• Macula
• Posterior pole
• Peripheral retina
• Optic nerve
• Neovascularization

Look specifically for:

• Hemorrhages
• Cotton-wool spots
• Microaneurysms
• Exudates
• Vascular attenuation
• NVD/NVE

Optical Coherence Tomography

OCT is the principal test for detecting and monitoring radiation maculopathy.

It demonstrates:

• Intraretinal fluid
• Cystoid spaces
• Subretinal fluid
• Retinal thickness
• Outer retinal damage
• Atrophy

Serial OCT is central to anti-VEGF treatment decisions.

OCT Angiography

OCTA can demonstrate:

• Capillary dropout
• Enlarged FAZ
• Superficial plexus abnormalities
• Deep capillary plexus abnormalities
• Neovascular complexes

It is especially useful for:

Early microvascular disease before dramatic funduscopic changes develop.

Fluorescein Angiography

FA may demonstrate:

• Microaneurysms
• Telangiectasia
• Capillary nonperfusion
• Enlarged FAZ
• Macular leakage
• NVD/NVE leakage

Wide-field FA can be particularly useful for quantifying:

Peripheral retinal ischemia.

Fundus Photography

Fundus photography is useful for documenting:

• Hemorrhage
• Exudation
• Neovascularization
• Evolution over time

Differential Diagnosis

Important differentials include:

• Diabetic retinopathy
• Retinal vein occlusion
• Hypertensive retinopathy
• Ocular ischemic syndrome
• Retinal artery occlusive disease
• Sickle cell retinopathy
• Retinal vasculitis
• Purtscher-like retinopathy
• Other ischemic retinopathies

Radiation Retinopathy vs Diabetic Retinopathy

The retinal appearance can be nearly identical.

Radiation retinopathy is favored by:

• Previous radiation exposure
• Distribution matching radiation field
• Unilateral/asymmetric disease after unilateral treatment
• Lack of comparable systemic diabetic retinal disease

A diabetic patient can, of course, have:

Both conditions simultaneously.

Radiation Retinopathy vs Retinal Vein Occlusion

Vein occlusion typically produces:

• Venous dilation/tortuosity
• Sectoral or diffuse hemorrhage pattern
• Corresponding venous drainage distribution

Radiation retinopathy tends to produce a more chronic microangiopathic pattern related to the irradiated retina.

Treatment Principles

Treatment is aimed at:

• Controlling macular edema
• Suppressing neovascularization
• Preventing vitreous hemorrhage
• Preventing neovascular glaucoma

Damage from established retinal nonperfusion itself is:

Usually irreversible.

Anti-VEGF Therapy

The modern first-line treatment for vision-threatening radiation maculopathy is:

Intravitreal anti-VEGF therapy

Common agents include:

• Bevacizumab
• Ranibizumab
• Aflibercept
• Other VEGF-inhibiting agents depending on availability

Anti-VEGF Effects

Anti-VEGF therapy may:

• Reduce macular edema
• Improve retinal thickness
• Stabilize visual acuity
• Improve vision in some patients
• Suppress retinal/iris neovascularization

Chronic Treatment Requirement

Radiation maculopathy is usually a:

Chronic disease

and anti-VEGF benefit frequently requires:

• Repeated injections
• Long-term surveillance

Stopping treatment may lead to:

• Recurrent edema
• Progressive vascular damage
• Visual decline

Treatment Regimens

Common approaches include:

• Fixed interval dosing
• PRN dosing
• Treat-and-extend strategies

Treatment is guided by:

• OCT fluid
• Visual acuity
• Hemorrhage
• Disease recurrence

Important Treatment Principle

Radiation maculopathy may require:

More persistent anti-VEGF treatment than many patients initially expect.

The goal is often:

Preservation of vision, rather than permanent cure.

Prophylactic Anti-VEGF

In patients receiving plaque brachytherapy for uveal melanoma, some centers use prophylactic intravitreal anti-VEGF injections before clinically apparent radiation maculopathy develops.

This strategy may:

• Delay macular edema
• Reduce severity of radiation maculopathy
• Improve long-term visual preservation

However:

Prophylactic anti-VEGF is not universally required or standardized for every irradiated eye.

Use depends on:

• Tumor location
• Macular radiation dose
• Patient risk
• Institutional protocol

Intravitreal Corticosteroids

Steroids may be useful for:

• Persistent radiation macular edema
• Incomplete anti-VEGF response

Options include:

• Dexamethasone implant
• Other intravitreal steroid approaches

Steroid Risks

Potential complications include:

• IOP elevation
• Cataract
• Infection

Therefore steroids are generally used selectively.

Focal/Grid Laser

Focal or grid laser was historically a major treatment for radiation macular edema.

Its role is now:

Much more limited

because anti-VEGF therapy generally provides better control of center-involving edema.

Laser may still have a role in selected:

• Non-center-involving focal leakage
• Chronic cases not suitable for injections

Panretinal Photocoagulation

PRP is indicated for significant proliferative radiation retinopathy, particularly when there is:

• NVD
• NVE
• Extensive ischemia with neovascular complications

Its purpose is to reduce:

Retinal ischemic VEGF drive

Anti-VEGF + PRP

For active neovascularization:

• Anti-VEGF produces rapid regression
• PRP provides more durable ischemia control

The combination is especially useful with:

• NVI
• NVA
• Neovascular glaucoma

Neovascular Glaucoma

Management includes:

• Intravitreal anti-VEGF
• PRP
• Aqueous suppressant medications
• Glaucoma surgery when necessary

Anti-VEGF alone is temporary because it does not eliminate the underlying retinal ischemia.

Vitrectomy

Pars plana vitrectomy may be required for:

• Nonclearing vitreous hemorrhage
• Recurrent vitreous hemorrhage
• Tractional retinal detachment
• Combined tractional/rhegmatogenous detachment
• Epiretinal traction in selected cases

Macular Ischemia

No established treatment restores retinal tissue lost from:

Macular capillary nonperfusion

Anti-VEGF may reduce coexisting edema but cannot reliably reverse established foveal ischemia.

Systemic Risk-Factor Control

Optimize:

• Diabetes
• Hypertension
• Dyslipidemia
• Smoking status
• Other vascular risk factors

This does not reverse radiation damage but may reduce additive microvascular stress.

Prevention

The most important preventive strategy is:

Minimizing unnecessary radiation exposure to the retina and macula during treatment planning.

Techniques include:

• Careful dosimetry
• Conformal radiation planning
• Shielding when feasible
• Plaque placement optimization
• Proton-beam targeting
• Fractionation where appropriate

Post-Radiation Surveillance

Patients receiving significant retinal radiation exposure should undergo:

Long-term ophthalmic surveillance

because disease may appear years after treatment.

Follow-Up

Frequency depends on:

• Radiation dose
• Tumor location
• Macular involvement
• Current retinal findings
• Active treatment

Stable high-risk patients may be examined every:

3–6 months

while active macular edema or neovascular disease often requires much closer follow-up.

Monitoring

Assess:

• Visual acuity
• IOP
• Slit-lamp examination
• NVI
• Gonioscopy when indicated
• Dilated fundus examination
• OCT

Use FA/OCTA when:

• Ischemia needs characterization
• Neovascularization is uncertain

Prognosis

Radiation retinopathy is:

Chronic and potentially progressive

Visual prognosis depends heavily on:

• Macular radiation dose
• Degree of macular ischemia
• Optic nerve involvement
• Time to treatment
• Response to anti-VEGF
• Development of neovascular complications

Early Treatment

Modern anti-VEGF therapy has substantially improved visual outcomes compared with historical observation or laser-only treatment.

Best outcomes occur when:

Macular edema is detected and treated before severe irreversible ischemic or structural damage develops.

Poor Prognostic Features

Poor visual prognosis is associated with:

• Severe macular ischemia
• Extensive capillary nonperfusion
• Chronic untreated edema
• Foveal atrophy
• Radiation optic neuropathy
• Vitreous hemorrhage
• Neovascular glaucoma
• Retinal detachment

Complications

Important complications include:

• Radiation macular edema
• Macular ischemia
• Retinal neovascularization
• NVD/NVE
• Vitreous hemorrhage
• Tractional retinal detachment
• NVI/NVA
• Neovascular glaucoma
• Permanent central visual loss
• Concurrent radiation optic neuropathy

Ophthalmology Pearls

• Radiation retinopathy is a delayed occlusive retinal microangiopathy after radiation involving the eye, orbit, or adjacent head and neck structures.
• The pathology resembles diabetic retinopathy because radiation produces endothelial injury, capillary leakage, and progressive nonperfusion.
• Typical findings include microaneurysms, cotton-wool spots, retinal hemorrhages, hard exudates, macular edema, and later neovascularization.
• Radiation maculopathy is the major cause of visual loss, particularly through macular edema and ischemia.
• Disease most commonly appears 1–3 years after radiation, but substantially later onset is possible.
• Risk increases with higher retinal dose, larger fraction size, macular/optic-disc exposure, diabetes, hypertension, and chemotherapy.
• OCT is the key modern test for radiation macular edema, while FA and OCTA demonstrate capillary nonperfusion and vascular abnormalities.
• Intravitreal anti-VEGF is now first-line treatment for vision-threatening radiation maculopathy, replacing focal/grid laser as the mainstay for center-involving edema.
• Anti-VEGF treatment is often chronic and repeated; interruption may lead to recurrent edema and visual deterioration.
• Intravitreal corticosteroids may help selected anti-VEGF–refractory cases but carry risks of IOP elevation and cataract.
• Prophylactic anti-VEGF after plaque brachytherapy is used in selected high-risk eyes and may delay radiation maculopathy, but it is not a universal requirement.
• PRP remains important for proliferative radiation retinopathy and retinal ischemia producing neovascularization.
• NVI/NVA should be managed with rapid anti-VEGF plus definitive retinal ischemia treatment with PRP, along with glaucoma therapy.
• Vitrectomy is reserved for complications such as nonclearing vitreous hemorrhage and tractional retinal detachment.
• Established macular ischemia is generally irreversible, so early detection of edema and vascular injury is critical.
• Patients require long-term surveillance, because radiation retinopathy may develop years after apparently successful cancer treatment.